Latest News
The US Food and Drug Administration (FDA) has granted clearance to ZetrOZ Systems’ sustained acoustic medicine device, the sam 2.0 wearable ultrasound unit, broadening its use for various medical conditions.
US-based ZetrOZ Systems has received expanded indication approval by the US Food and Drug Administration (FDA) for its sam 2.0 long-duration wearable ultrasound unit to treat soft tissue injuries and knee osteoarthritis.
If you've ever experienced a running injury (or had a baby), you're probably familiar with ultrasound as a diagnostic imaging tool. For years, ultrasound has also been used as a therapeutic tool, and recent advances in technology have made it possible to miniaturize the technology for home use, at much lower intensity and for longer duration than it is used in a clinical setting. The research is not extensive, and it's not cheap. But some runners have found it to be the thing that works where nothing else does.
We have designed sustained acoustic medicine (sam®), a wearable ultrasound device that reduces the need for surgery and pain medication, and can be used by the patient during daily activities. The sam® family of products are the only wearable long-duration mobile ultrasound therapy devices approved by the FDA to provide therapy for up to four hours daily.